Nsidered well enough to tolerate the Abiraterone CB-7598 treatment, although there are no clear guidelines regarding the optimal timing of treatment. However, one notable difference is that w During EAU guidelines do not list an advanced age as a criterion for the non-issuance of chemotherapy, our fi ndings that many lay Close to older patients with advanced prostate cancer in Gro Britain not re oivent no chemotherapy with docetaxel, for which a significant cant survive t receiver singer was shown. Furthermore, as the analysis of subgroups showed that the economic cabazitaxel and docetaxel significantly cant just off Older people, the decision not to be with chemotherapy alone based on age seems unjustified to treat. Interestingly, these ndings Fi are also in contrast to the situation in advanced breast cancer where oncologists are more likely chemotherapy will be carried out, even with these regulations, which has non-global t be cloudy with leads receiver Survive singer. However, the reasons for these apparent differences in clinical practice are unclear. Regarding the choice of chemotherapy, 44% of oncologists felt included in our survey that they are very likely to use cabazitaxel in their clinical practice for the n Chsten 5 years were with another 35% indicating that this was a M Opportunity. These fi ndings are not surprising, the impressive data reported phase III trial for this agent, which showed that the treatment was associated with cabazitaxel with a significant improvement in overall survival and progression-free survival, compared with the given mitoxantrone at M Nnern with mCRPC whose disease w progressed during or after treatment with docetaxel is. In addition, as already cabazitaxel mCRPC United States has approved and again U pan-European licensing agreement of the Union, it is very probable that the standard be Britain cabazitaxel second-line chemotherapy option in Gro MCRPC patients. Other agents in our survey identifi as likely a great influence on clinical practice in Gro Britain in the n Chsten 5 years were abiraterone acetate and MDV3100. Abiraterone acetate is a stero Selectively and irreversibly inhibits serving both the hydroxylase and C17 17, 20 lyase function of CYP17A1, a cytochrome in the production of dehydroepiandrosterone and androstenedione. The F Promotion antitumor activity t was was reported with abiraterone acetate at a dose of 1000 mg / day in the different populations of CRPC by several phase II studies. More recently, fi ndings from a phase III study has shown that abiraterone survive acetate and low dose prednisone significantly reduced the overall survival, time to PSA progression, progression-free and PSA response rates improved compared to placebo in M Nnern with mCRPC who had progressed after treatment with docetaxel. Based on these data, abiraterone acetate was used recently U, the U.S. Food and Drug Administration for use in combination with prednisone for the treatment of patients who mCRPC again U prior Temsirolimus chemotherapy with docetaxel. Abiraterone has now again U pan-European licensing approval by the EMA. In addition, there was a second phase III trial of abiraterone acetate and low dose prednisone nnern at M Fs mCRPC chemotherapy is underway. Therefore, it is likely that, as they become available, there is a significant überh Increase and rapid absorption of the use of abiraterone acetate in the United K Kingdom.